Results 161 to 165 of about 2,530 (165)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies, 2023
CADTH recommends that Beovu be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met. Beovu should be covered to treat patients with DME provided that Beovu is covered for a similar patient population and in a similar way to other anti–vascular endothelial growth factor (VEGF) drugs
openaire +1 more source
CADTH recommends that Beovu be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met. Beovu should be covered to treat patients with DME provided that Beovu is covered for a similar patient population and in a similar way to other anti–vascular endothelial growth factor (VEGF) drugs
openaire +1 more source
Drugs, 2019
Brolucizumab (Beovu®) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Based primarily on the results of the
openaire +2 more sources
Brolucizumab (Beovu®) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Based primarily on the results of the
openaire +2 more sources